45 results about "Tumor Weight" patented technology

The invention relates to application of protosappanin B, in particular to application of a 0.2 to 2.4 percent protosappanin B solution in preparation of bladder cancer resistant perfusion fluid. For filling up the research blank of the protosappanin B at home and abroad, the invention provides new application of the protosappanin B. Human bladder cancer cell strains T24 or mouse bladder cancer cell strains BTT are inoculated to mouse bodies to form bladder cancer, and the mice are grouped and respectively subjected to experiments with injection water, mitomycin and the protosappanin B; experiment results show that the lives of the mice injected with the mitomycin and the protosappanin B are prolonged, the tumor weight is reduced, and a tumor inhibiting effect is achieved; and the protosappanin B has a remarkable bladder cancer inhibiting effect, and can be widely applied to preparation of the bladder cancer resistant perfusion fluid.

The invention relates to the field of gene therapy and discloses a fixed-point knockout system for high-risk HPV (human papilloma virus) E6E7 gene, namely targeted cutting of TALENs (transcription activator-like effector nucleases) of HPV E6E7 gene, wherein a TALENs expression vector of the target specific site is designed according to the high-risk HPV E6E7 gene sequence, and the HPV E6E7 gene sequence in the cells are cut in a targeted manner so as to knock out the target gene and induce the apoptosis increase and proliferation inhibition of corresponding subtype cells while the TALENs do not act on the HPV positive or HPV negative cells of other subtypes. By transfecting the TALEN expression vector in a subcutaneous tumor model of HPV positive cervical cancer cells, the growth of subcutaneous tumor can be obviously inhibited, and the tumor weight is reduced. According to the method for targeted knockout of high-risk HPV E6E7 gene using TALEN provided by the invention, the virus oncogene can be efficiently broken on the DNA level so as to cause apoptosis and proliferation inhibition of the HPV infected cells, and the method is of tremendous therapeutic value on HPV infection related diseases and particularly precancerous lesions such as cervical intraepithelial neoplasias.

The invention discloses a Leu-Asp-Val modified curcumin and oligopeptide conjugate of the following formula, a preparation method thereof, its activity of inhibiting tumor cell proliferation, its effect of inhibiting migration and invasion of A549 cells, its activity of inhibiting S180 tumor-bearing mice tumor weight increase, its activity of inhibiting Lewis lung cancer metastasis, its activity of inhibiting xylene induced mice ear swelling, and further discloses its activity of inhibiting rat thrombosis.

The invention mainly relates to application of ginsenoside Ro in the preparation of antitumor drugs. Experiments for studying on changes in the size of tumors of a mouse injected with ginsenoside Ro show that early inhibition rate for the growth of tumors in the mouse injected with the ginsenoside Ro is substantially unchanged and the tumors enlarge synchronously with tumors in model group animals; after entering logarithmic growth stage, the ginsenoside Ro has enhanced inhibitory action on the enlargement of the tumors, and the inhibition rate is significantly higher than the tumor growth inhibitory action in slow growth stage; it is proved that the ginsenoside Ro has good inhibitory action on mouse melanoma. According to tests for researching change of tumor weight of the mouse injected with the ginsenoside Ro, the ginsenoside Ro has good inhibitory action on the melanoma and can be prepared into new antitumor drugs.

The invention discloses an amine compound, the structure of which is , and discloses the synthesis route, synthesis steps and application of the amine compound in antitumor drugs. In vitro pharmacological experiments have found that the amine compound has inhibitory activity on various human cancer cells, and in vivo pharmacological experiments have a significant effect on reducing tumor weight in nude mouse xenograft cancer models of human liver cancer.

The invention provides application of FGFR1-MIP3 Alpha/Fc fusion protein in the preparation of targeted anti-breast cancer drugs. The FGFR1-MIP3 Alpha/Fc fusion protein vaccine is discovered to be capable of obviously inhibiting the growth of 4T1 mouse breast cancer, the size of the tumor is obviously reduced, and the weight of the mouse and the weight of the tumor are obviously reduced; althoughthe FGFR1-Fc or MIP3 Alpha-Fc immunotherapy group has a certain degree of anti-tumor effect alone, the effect is not as good as the effect of the FGFR1-MIP3 Alpha group; and meanwhile, obvious toxic and side effects are not discovered in the process of experiment.

The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.

The invention discloses application of purple sweet potato polysaccharides in preparation of lung cancer resistant drugs. The purple sweet potato polysaccharides are heteropolysaccharides extracted from Ningzi #4 purple sweet potatoes, and are mainly composed of three kinds of monosaccharides of xylose, rhamnose and glucose, wherein the xylose content is 84.92+/-1.57%, the rhamnose content is 2.15%, the glucose content is 0.57%, and the average molecular weight is 0.82*10<4>Da. The purple sweet potato polysaccharides have effects of obviously inhibiting cell proliferation of lung cancer cellssuch as A549, H1299 and H460, the BALB/c mouse subcutaneous tumor volume subjected to purple sweet potato polysaccharide FsPSP-1 treatment is obviously reduced, and the tumor weight is obviously reduced. The invention provides novel application of the purple sweet potato polysaccharides in preparation of lung cancer resistant drugs, the application field of the purple sweet potato polysaccharidesis broadened, a material basis is provided for developing natural activity antitumor drugs, and the application has potential social benefits and economic benefits.

The invention discloses a composition for inhibiting glioma growth and an application thereof. The composition comprises a substance for improving the expression of protein (PTEN) as shown in sequence 1 of the sequence table, and a substance for inhibiting the expression of protein (B) as shown in sequence 3 of the sequence table. Experiments demonstrate that when the combination of recovering the expression of protein PTEN with inhibiting the expression of protein B is compared with only recovery of the expression of protein PTEN or only inhibition of expression of protein B, the AKT phosphorylation level of recombinant glioma cell lines is significantly decreased, cell proliferation and colony formation are significantly inhibited, and the proportion of cells stopping at the G0/G1 phase and the cell apoptosis rate are significantly increased; Glioma in transplanted mouse body has no increase in size at 20-48 days after treatment by recovering the expression of protein PTEN combined with inhibiting the expression of protein B, and the tumor weight is almost zero at the 48th day after the treatment. The invention provides a new and effective combination therapy scheme for glioma, and has wide application prospects.

The invention discloses application of 1,2,3,4,6-pentagalloylglucose, or an optical isomer, or a racemate, or a solvate, or a pharmaceutically acceptable salt in the preparation of drugs for the treatment or prevention of renal cancer or prostate cancer. According to the application, an experiment shows that the 1,2,3,4,6-pentagalloylglucose can significantly reduce the cell activity of Renca renal cancer and RM-1 prostate cancer in vitro, can reduce the tumor weight of tumor bearing mice in vivo, and it is proved that the 1,2,3,4,6-pentagalloylglucose has an inhibitory effect on two kinds oftumors, and PD-L1 gene expression is detected in two kinds of tumor bearing mice, so that it can be preliminarily inferred that the 1,2,3,4,6-pentagalloylglucose may play an anti-tumor role mainly byblocking PD1/PD-L1.

The invention discloses a curcumin and oligopeptide Tyr-Ile-Gly-Ser-Arg conjugate of the following formula, a preparation method thereof, its activity of inhibiting tumor cell proliferation, its effect of inhibiting migration and invasion of A549 cells, its activity of inhibiting S180 tumor-bearing mice tumor weight increase, its activity of inhibiting Lewis lung cancer metastasis, its activity of inhibiting xylene induced mice ear swelling, and further discloses its activity of inhibiting rat thrombosis.

The invention provides application of fenofibrate to preparation of antitumor medicine, in particular to application of fenofibrate to reparation of chemotherapy medicine sensitization medicine. The fenofibrate has the obvious inhibition effect on the tumor growth; the volume of the tumor body is reduced; the tumor weight is reduced; no obvious liver and kidney toxicity and whole body toxic and side effects exist; the obvious cooperated effect is achieved when the fenofibrate is used in a way of being combined with chemotherapy medicine; the sensitivity of the tumor on the chemotherapy medicine can be enhanced; the chemotherapy toxicity cannot be increased by the combined use of the fenofibrate and the chemotherapy medicine; in addition, under the condition of reaching the same tumor inhibition effect, the toxic and side effects of the chemotherapy can be reduced through reducing the consumption of the chemotherapy medicine.

The invention relates to an application of trichoderma pseudokoningii exopolysaccharide as a medicine for treating a gastric cancer, and belongs to the technical field of a medicine and health food. Trichoderma pseudokoningii exopolysaccharide with an antitumor activity provided by the invention can obviously inhibit the growth of human gastric cancer cells BGC-823, MKN-45 and MGC-803 through in vitro administration; explosion of an reactive oxygen in the BGC-823 cell and decreasing of a mitochondrial membrane potential are caused, so that nucleic acid in a tumor cell is cracked, a DNA (deoxyribonucleic acid) segment is produced, a BGC-823 cell cycle is stopped at an S stage, and finally, apoptosis of cancer cells occurs, and therefore, the antitumor effect is produced. The medicine administrated in vivo can inhibit tumor growth of a BGC-823 tumor-bearing mouse, an MKN-45 tumor-bearing mouse and an MGC-803 tumor-bearing mouse, and relieves tumor weight, so that trichoderma pseudokoningii exopolysaccharide has a remarkable antitumor effect.

The invention discloses an antineoplastic purpose of taro leaf polysaccharide. According to the invention, Liver cancer cells Huh7 are inoculated in subcutaneous positions of nude mice to form tumor;at the same time, the taro leaf polysaccharide is subjected to intervention; and the body weight change condition of the nude mice in the experiment process is monitored. After the intervention experiment is completed, the subcutaneous tumor is peeled; the tumor weight is recorded; the cell factor secretion condition in the serum is monitored; and the taro leaf polysaccharide has obvious anti-tumor effect.

The present invention relates to a method of treating leukemia using rice prolamin, comprising administering a daily dose of isolated prolamin to a patient suffering from leukemia for a period of time from 5 days to 10 days. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear cell (PBMC) to produce cytokines, such as tumor necrosis factor-alpha, to inhibit growth of and induce differentiation of human leukemia cells. The rice prolamin is gluten-free, thus will not trigger gastrointestinal allergic reaction, it also can decrease the tumor weight without changes in body weight and can inhibit the growth of peripheral blood leukocyte in leukemia mouse model.

The invention discloses an application of a lotus leaf alcohol extract in preparation of a drug for inhibiting cancer metastasis and belongs to the technical field of biomedicine. Mice suffering frommetastatic cancer are used as experimental subjects, compared with a control group fed with normal feed, the mice which suffer from the metastatic cancer and are fed with feed containing the lotus leaf alcohol extract have obviously reduced weight and have the lung metastasis number reduced by about 45% and the total tumor weight at the metastasis part reduced by about 50%. The fact that the lotusleaf alcohol extract can be used for effectively inhibiting cancer metastasis is put forward for the first time, so that a new way is opened up for treatment of metastatic tumor, great significance is made in the development of edible and medicinal dual-purpose resources, high-value conversion of active plant resources is realized, and deep processing and utilization of agricultural products is promoted.

A synthetic peptide sp4 has an amino acid sequence shown in SEQ ID NO: 1. As the sole effective ingredient in the antitumor efficacy test, it has a significant inhibitory effect on both the tumor volume and tumor weight of human osteosarcoma MG-63 in nude mice and has a significant dose-effect and time-effect relationship. There is no difference between the relative tumor growth rate T/C (%) of sp4 and that of the positive control group of Paclitaxel. The safety of sp4 is that its maximal tolerated dose for intravenous administration is 700 mg/kgBW. Sp4 has clear targets of pharmacological effects, while having efficacy in vivo, it also has an inhibitory effect on tumor telomerase, has an arrest on G1 phase of the tumor cell cycle, and inhibits the high expressions of tumor PD-L1 and CD47. The present disclosure relates to multiple uses of sp4, especially in the preparation of a class of antitumor drugs.

An application of a glucocorticoid receptor accelerator antcin A in inhibiting tumorigenesis and metastasis of breast cancer is disclosed, human breast cancer cells MCF-7 and MDA-MB-231 are treated byutilizing natural glucocorticoid analog antcin A, and then an miR-708 expression is significantly increased by activating a glucocorticoid receptor [alpha] (GR[alpha]). Induction of the miR-708 expression by a GR accelerant can effectively inhibit proliferation of human breast cancer cells, a cell cycle progression, and tumor stem cell expression and cancer cell metastasis. In addition, the GR accelerant or an miR-708 transfection treatment cell significantly inhibits an expression of IKK[belta], also inhibits the activity of NF-[kappa]B and the expression of its downstream target genes, andimproves amount of expression of involvement in cancer cell proliferation, the cell cycle progression, metastasis and cancer stem cells marker proteins p21<CIP1> and p27<KIP1>. Human breast cancer cell xenograft model tests find that treatment of animals with the GR accelerant can significantly inhibit tumor growth and tumor weight and volume. As a whole, a result of an experiment strongly speculates that the GR accelerant induces the miR-708 expression and inhibits NF-[kappa]B downstream signal transduction, and can be a novel treatment mode applied to breast cancer treatment.

The invention discloses a medicament for treating endoplasmic reticulum (ER) breast cancer and belongs to the technical field of pharmacy. The active ingredients of the medicament are arsenic trioxide and tamoxifen. Experiments show that after being used together, the arsenic trioxide and the tamoxifen have obvious effect. To inoculated BALB/c-nu female nude mice, the tumor volume inhibition ratio of the composite medicament is up to 77.42 percent and the tumor weight inhibition ratio of the medicament is up to 76.28 percent. In addition, the formulation of the medicament is also improved, namely the arsenic trioxide is wrapped through collagen and then is mixed with the tamoxifen; and after a proper amount of diluent is added into the mixture, the mixture is prepared into oral formulations, such as powder, pills or capsules and the like. A normally used food component, namely water-soluble collagen, serves as a carrier and has high entrapment efficiency to the arsenic trioxide; the in-vivo retaining time of the arsenic trioxide can be prolonged while the side effect of the arsenic trioxide on gastrointestinal tract is reduced; long-time effective blood concentration is maintained; and while the effect of the medicament is maintained, great convenience is brought to patients and the injection pains of the patients are relieved.